1. Scrip
  2. >>Business
  3. >>Earnings

Moderna Teases M&A Interest As Pandemic Expected To Wind Down

Biotech Anticipates Four Phase III Programs In Clinic in Q2

 
• By Alaric DeArment

Spikevax revenues beat expectations but analysts are bracing for the eventuality of lower vaccine revenues as COVID-19 becomes endemic. Moderna will have four new vaccines in Phase III this quarter.

Moderna and Pfizer covid vaccines
Moderna announced its first quarter 2022 earnings • Source: Shutterstock

Speculation that Moderna, Inc.’s Spikevax windfall could lead to an interest in mergers and acquisitions has gained added substance as the company indicated during its first quarter sales and earnings call that it is looking at potential deals around the world. At the same time, while Q1 revenues beat consensus expectations, analysts are bracing for the possibility of lower revenue as the COVID-19 pandemic becomes endemic.

The company unveiled its first quarter earnings on 4 May, including revenues that beat analyst estimates and projections that it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By Andy Smith

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 
• By Anju Ghangurde

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

J&J Delivers In Q2 Despite Stelara Drop, Raising Guidance

 
• By Jessica Merrill

Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.

More from Business

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.